“Antibiotic resistance is a global crisis” WHO, 2015
Antibiotic resistance is a growing concern in healthcare, one that the World Health Organization called a “global health crisis” as far back as 2015. Recent research has suggested that antibiotic-resistant bacteria are highly prevalent in hospital settings so alternatives to antibiotics are being sought globally as a matter of urgency for public health. A growing list of conditions, such as pneumonia and tuberculosis, are already becoming difficult to treat due to this resistance. One possible alternative solution being studied is Cannabidiol (CBD), extracted from the Cannibis Sativa Hemp plant.
CBD oil has been shown to possess antimicrobial properties, making it another tool for fighting infection. Although it is not well-understood how CBD fights bacteria, studies have confirmed CBD’s antibiotic properties, which are particularly useful in attacking bacteria that have become resistant to traditional antibiotics. One such study investigated how various cannabinoids, including CBD and tetrahydrocannabinol (THC), affect pathogenic bacteria (1,2). In this study, each cannabinoid was tested against six strains of the antibiotic-resistant superbug, methicillin-resistant Staphylococcus aureus (MRSA). All cannabinoids showed potent activity against a variety of MRSA strains. These results were encouraging showing that CBD can be effective at fighting one of the most treatment-resistant strains of bacteria the field of medicine has ever seen.
Recently, further in vitro and in vivo, animal studies demonstrated that CBD could kill numerous strains of Staphylococcus aureus, including antibiotic-resistant Gram-positive bacterial strains like VRSA, VISA, and MRSA, without showing any resistance to CBD (3,4). These studies showed CBD to be effective at killing Staphylococci, Enterococci and Streptococci bacteria, responsible for some skin, gut and throat infections. CBD has also been found to be effective at disrupting biofilms, a microscopic conglomeration of bacteria, mucopolysaccharides, and waste products which act as a physical barrier preventing antibiotics from stopping bacterial growth.
Researchers from The University of Queensland have shown that CBD is capable of penetrating and killing the bacteria responsible for conditions including legionnaires disease, gonorrhea, and meningitis (3). “This is the first time CBD has been shown to kill some types of Gram-negative bacteria. These bacteria have an extra outer membrane, an additional line of defence that makes it harder for antibiotics to penetrate,” The UQ Institute for Molecular Bioscience’s Associate Professor Dr. Mark Blaskovich reported. The bacteria responsible for gonorrhea is especially adept at developing antibiotic resistance. Currently, there is no single “gold standard” antibiotic for universal gonorrhea treatment.
During an infection, membrane vesicles released from bacteria participate in cell communication and host-pathogen interactions. Studies using CBD with both Gram-positive and Gram-negative bacteria have indicated that CBD may pose as a potent agent for tailored co-application with selected antibiotics, depending on bacterial species, to increase antibiotic activity, including via membrane vesicle inhibition, and help reduce antibiotic resistance (5). This breakthrough in microbiology could ultimately lead to the development of new treatments. Scientists hope that this breakthrough could eventually lead to the production of a new class of non-resistant antibiotics.
These promising, recent developments need further research in animal and human studies as well as more research into the exact mechanism of action of CBD against various micro-organisms. CBD could prove especially helpful for specific conditions due to a combination of antibiotic and anti-inflammatory effects. This unique combination may help reduce inflammatory tissue damage in infections. Many studies show that CBD is a potent anti-inflammatory agent. Cannabinoids effectively bind to natural CB1 and CB2 cannabinoid receptors within the endocannabinoid system (ECS), located throughout the body, including the central nervous system and some peripheral tissues – immune cells, adipose tissue, liver, kidney, lungs, muscle and reproductive cells (CB1) and peripheral immune system, gastrointestinal tract, heart, liver and, at low density in the central nervous system (CB2), (6). Since CBD is an immune modulator, this could, in part, explain its anti-microbial properties. Indeed, this “wonder drug” is proving to be so advantageous to helping the disease state in both humans and animals, that we all need to be taking it! Go to Pure Organic CBD to order yours today!
- Appendino, G et al. (2008) Antibacterial Cannabinoids from Cannabis sativa: A Structure−Activity Study. J. Natural Products 71 (8), pp 1427-1430.
- Methicillin-resistant Staphylococcus aureus (MRSA). Accessed Feb 2021: https://www.cdc.gov/mrsa/community/index.html
- Blaskovich M (2019) https://imb.uq.edu.au/article/2019/06/cannabis-compound-could-be-powerful-new-antibiotic
- General Information about VISA/VRSA. Accessed Feb 2021: https://www.cdc.gov/hai/organisms/visa_vrsa/visa_vrsa.html
- Kosgodage US, Matewele P, Awamaria B, et al. (2019) Cannabidiol Is a Novel Modulator of Bacterial Membrane Vesicles. Front Cell Infect Microbiol. 9:324.
- Pacher P., Batkai S., Kunos G. (2006) The Endocannabinoid System as an Emerging Target of Pharmacotherapy. Pharmacol. Rev. 58 (3) pp389-462